
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure Inc. reported strong revenue growth of $124.3 million in Q4 2024, reflecting a year-over-year increase of 16.6%, with significant contributions from both its cardic ablation and pain management product lines. The company's R&D expenditure represented 28.1% of sales, which was notably higher than anticipated, driven by a substantial $12 million upfront payment for a co-development agreement, indicating robust investment in innovative product development. Furthermore, AtriCure's EBITDA margin improved to 10.2%, surpassing consensus estimates, highlighting efficient cost management and a favorable outlook for continued revenue expansion driven by new product launches and growing market demand.
Bears say
AtriCure Inc faces several fundamental challenges, including disappointing sales from key products and increasing market share loss to competitors, particularly with Medtronic's Penditure device impacting their left atrial appendage management segment. Revenue growth has decelerated, dropping to 17% in the fourth quarter of 2024 from 18% in the third quarter, driven by lower performances in minimally invasive ablation and appendage management. Additionally, the company has experienced declines in both gross margin and operating margin, with the gross margin at 74.5%, which fell short of expectations, signifying pressures from unfavorable product and geographic mix that may further hinder financial performance.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares